ÂÜÀòÂÒÂ×

Dr. Deehan joined Vivtex in December 2022 as the Chief Business & Operating Officer and was promoted to Chief Executive Officer in February 2023. She is a PhD qualified biotechnology and pharmaceutical professional with 22 years of drug development and commercialization experience. She obtained her PhD from the Faculty of Medicine at Glasgow University, and subsequently spent 8 years in academic research before moving into industry in 2001. During her early days in industry, she was responsible for high throughput screening technologies and activities at Organon Laboratories. Maureen has gained expertise in all stages of the drug development cycle from discovery to product commercial launch, across a broad range of therapeutic areas, including CNS, Oncology, Immunology, Cardiovascular and Women’s Health. Her last 9 years have been spent in global corporate development roles at Novimmune SA and Nordic Nanovector ASA where she has gained a successful track record in business development and deal-making, for product and technology platform transactions, with a range of companies, including Genentech and Shire.